文章：

淋巴瘤双特异性抗体治疗期间的可测量残留病检测

Measurable Residual Disease Testing During Treatment with Bispecific Antibodies for Lymphoma

原文发布日期：29 March 2025

DOI: 10.3390/cancers17071153

类型: Article

开放获取: 是

英文摘要：

The introduction of bispecific antibodies (BsAbs) has led to significant improvements in survival for patients with relapsed and refractory B-cell lymphomas. Despite these advances, there remains a significant number of patients who experience disease progression after these novel therapies. Predicting which patients may respond to certain treatments and the durability of their responses remains challenging. Measurable residual disease (MRD) has become easier to detect and quantify through the use of genomic next-generation sequencing tools and has been studied as a possible biomarker to predict long-term outcomes and risk-stratify patients after BsAb therapy in several lymphoma subtypes. Here, we review recent data demonstrating that MRD negativity is associated with radiographic response and improved progression-free survival. Because of heterogeneity in assay choice, assessment timing, and technical parameters, further work is needed before MRD testing is ready to be incorporated into clinical practice in the context of BsAb treatment for B-cell lymphomas.

摘要翻译： 

双特异性抗体（BsAbs）的引入显著改善了复发难治性B细胞淋巴瘤患者的生存状况。尽管取得了这些进展，仍有相当数量的患者在接受这些新型疗法后出现疾病进展。预测哪些患者可能对特定治疗产生反应以及其反应的持久性仍然具有挑战性。通过使用基因组下一代测序技术，可测量残留病（MRD）的检测和定量变得更加容易，并且已在多种淋巴瘤亚型中作为预测BsAb治疗后长期结局和风险分层的潜在生物标志物进行研究。本文综述了近期数据，表明MRD阴性状态与影像学缓解及改善的无进展生存期相关。由于检测方法选择、评估时机和技术参数存在异质性，在将MRD检测纳入B细胞淋巴瘤BsAb治疗的临床实践之前，仍需进一步研究。

原文链接：

Measurable Residual Disease Testing During Treatment with Bispecific Antibodies for Lymphoma